1. Home
  2. GLPG vs PHVS Comparison

GLPG vs PHVS Comparison

Compare GLPG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$32.32

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.89

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
PHVS
Founded
1999
2015
Country
Belgium
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
GLPG
PHVS
Price
$32.32
$25.89
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$31.33
$39.44
AVG Volume (30 Days)
86.3K
532.0K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$336,643,201.00
N/A
Revenue This Year
$3.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.31
N/A
52 Week Low
$22.36
$11.51
52 Week High
$37.78
$29.80

Technical Indicators

Market Signals
Indicator
GLPG
PHVS
Relative Strength Index (RSI) 56.94 54.34
Support Level $30.73 $23.79
Resistance Level $32.75 $25.44
Average True Range (ATR) 0.60 1.91
MACD 0.07 -0.17
Stochastic Oscillator 78.52 41.22

Price Performance

Historical Comparison
GLPG
PHVS

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: